Loading...
T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics
Harnessing the power of the human immune system to treat cancer is the essence of immunotherapy. Monoclonal antibodies engage the innate immune system to destroy targeted cells. For the last 30 years, antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity have been the m...
Saved in:
| Published in: | Pharmacol Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5785550/ https://ncbi.nlm.nih.gov/pubmed/28834699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2017.08.005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|